Busulfan Therapy in Myeloid Metaplasia

Oishi, Noboru; Swisher, Scott N.; Troup, Stanley B.

doi:10.1182/blood.v15.6.863.863

Cited by 17 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Busulfan, an alkylating drug, can also be used to treat symptomatic splenomegaly 24 but, due to its prolonged effect and the risk of provoking long-lasting cytopenias, it requires a close control of the patients, making it inconvenient in clinical practice. Busulfan is contraindicated in the presence of leukocytes <4 × 10 9 /l or platelets <100 × 10 9 /l, as the drug accumulates in the bone marrow, where it continues exerting its effect for several weeks.…”

Section: Myelosuppressive Therapymentioning

confidence: 99%

How I treat splenomegaly in myelofibrosis

Cervantes

2011

Blood Cancer Journal

View full text Add to dashboard Cite

Symptomatic splenomegaly, a frequent manifestation of myelofibrosis (MF), represents a therapeutic challenge. It is frequently accompanied by constitutional symptoms and by anemia or other cytopenias, which make treatment difficult, as the latter are often worsened by most current therapies. Cytoreductive treatment, usually hydroxyurea, is the first-line therapy, being effective in around 40% of the patients, although the effect is often short lived. The immunomodulatory drugs, such as thalidomide or lenalidomide, rarely show a substantial activity in reducing the splenomegaly. Splenectomy can be considered in patients refractory to drug treatment, but the procedure involves substantial morbidity as well as a certain mortality risk and, therefore, patient selection is important. For patients not eligible for splenectomy, transient relief of the symptoms can be obtained with local radiotherapy that, in turn, can induce severe and long-lasting cytopenias. Allogeneic hemopoietic stem cell transplantation is the only treatment with the potential for curing MF but, due to its associated morbidity and mortality, is usually restricted to a minority of patients with poor risk features. A new class of drugs, the JAK2 inhibitors, although also palliative, are promising in the splenomegaly of MF and will probably change the therapeutic algorithm of this disease.

show abstract

Section: Myelosuppressive Therapymentioning

confidence: 99%